
HSS Achieves 100% Success Rate for Sedation-Free Pediatric MRIs
LAS VEGAS--(BUSINESS WIRE)--A study from Lerner Children's Pavilion at Hospital for Special Surgery (HSS) of nearly 2,000 children showed that pediatric MRIs were completed with a 0% sedation rate through the support of certified child life specialists (CCLS). The findings, which highlight how this innovative and noninvasive approach eliminated the need for sedation while improving care for young patients, were presented at the Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting.
Challenges of Pediatric MRIs
A typical MRI is not only loud and confining but also very sensitive to motion, requiring subjects to lie still during the 20- to 80-minute procedure, which is a major challenge for pediatric patients. Consequently, sedation is used in up to 28% of pediatric MRIs, and reports show this number is increasing.
While sedation can facilitate successful imaging—and is considered relatively safe—relying on this strategy for young MRI patients poses potential risks, including cardiopulmonary issues and allergic reactions. Additionally, the combination of MRIs and sedation can cause anxiety for children and their parents and prolong recovery.
Researchers found that avoiding anesthesia—and post-anesthetic recovery—through CCLS interventions improves the overall efficiency of the MRI process, benefiting both families and care teams.
'Without anesthesia, children can avoid the need for an IV, they don't need to fast prior to the MRI, and they don't need to extend their hospital-related experience to recover,' says lead study author Jessica H. Heyer, MD, pediatric orthopedic and spine surgeon at HSS. 'And from a hospital perspective, it enables children to have an MRI even when an anesthesiologist is not available.'
The American Academy of Pediatrics stresses that these types of nonpharmacological interventions 'must be considered as standard procedure in infants, children, and adolescents undergoing MRI,' supporting the approach taken in this study.
Benefits of Avoiding Sedation
For this retrospective cohort study, HSS researchers looked at 1,936 patients between the ages of 4 and 12 who, in total, received 2,319 MRI scans over an eight-year period. They found that no child who received CCLS intervention prior to and/or during the procedure required IV sedation during MRI.
Despite the study's remarkable success rate, Dr. Heyer notes that there are always exceptions: 'Sedation-free MRI may be more difficult for very young children, those who need longer scans, children with cerebral palsy, and for those who need a head, brain, or neck MRI."
While all children can greatly benefit from CCLS intervention, Dr. Heyer notes that children between ages 5 and 10 appear to show the strongest results. Study co-author Melissa Collins, MS, senior child life specialist at HSS, adds that this strategy is particularly valuable for children with sensory processing issues or those with a history of negative medical experiences. 'For example, children who've been told a procedure wouldn't hurt and then were held down or experienced pain are less likely to trust medical professionals and medical environments,' she says.
Effective Child Life Techniques
The researchers examined several CCLS techniques, including guided imagery, distraction strategies, and caregiver involvement, but the most helpful strategy is 'appropriate preparation based on the patient's developmental age,' says Collins. 'MRI anxiety typically stems from uncertainty, so it's important to provide children with accurate expectations, so they're able to prepare and cope more effectively.' Collins suggests showing children a video of an MRI that walks them through each step and what they'll see, hear, and feel during the scan to help take away some of the fear of the unknown. 'It also helps to reiterate that nothing is going to touch them or hurt them,' she says.
At the Lerner Children's Pavilion, one or both parents are always encouraged to accompany their child into the MRI suite. Children are also invited to bring a favorite soft, metal-free toy into the MRI unit and are given mirrored glasses so they can see their caregiver or the technologist behind them throughout the MRI. To celebrate their bravery, each child receives a small reward at the end of the exam.
Looking Forward
'Our research demonstrates that with proper preparation and support, we can transform a potentially stressful medical procedure into a positive experience for children,' concludes Dr. Heyer. 'By reducing the need for sedation, we're not only reducing medical risks but also empowering children to actively participate in their healthcare journey, potentially making future medical encounters less intimidating.'
Reference:
Tracey OC, Zucker C, Wisch J, Adhiyaman A, Thakur A, Collins M, Parise J, Denneen J, Jaramillo D, Potter H, Ipp L, Heyer JH. Not Just Fun and Games: Certified Child Life Specialists Improve Success Rates of Young Children Undergoing MRI Studies without Anesthesia. Presented at: Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting, 2025
Thestrup J, Hybschmann J, Madsen TW, et al. Nonpharmacological interventions to reduce sedation and general anesthesia in pediatric MRI: a meta-analysis. Hosp Pediatr. 2023;13(10):e301-e313. Accessed May 14, 2025, at https://doi.org/10.1542/hpeds.2023-007289
Uffman JC, Tumin D, Raman V, Thung A, Adler B, Tobias JD. MRI Utilization and the Associated Use of Sedation and Anesthesia in a Pediatric ACO. J Am Coll Radiol. 2017 July;14(7):924-930. Accessed May 14, 2025, at https://www.jacr.org/article/S1546-1440(17)30121-7/abstract
About HSS
HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report 'Best Children's Hospitals' list (2024-2025). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fifth consecutive year (2025). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
34 minutes ago
- Associated Press
FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
HANOI, Vietnam--(BUSINESS WIRE)--Jun 6, 2025-- Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. This press release features multimedia. View the full release here: FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system. Mr. Darrell Oh, Chairman of Pharma Group, said: 'Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam's most vital asset: its people.' Dr. Truong Gia Binh, FPT Chairman, stated: 'To accompany Vietnam's new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world's most advanced industries.' AI in Pharma: A Global Trend and an Opportunity for Vietnam Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%. Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: 'AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain.' He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam's pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN's leading AI hub by 2028. Achieving Resolution 57 and National Goals for Healthcare Breakthroughs As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups. Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: 'AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access.' He further stated: 'FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era.' About Pharma Group Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients. Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment. About FPT Corporation FPT Corporation is Vietnam's leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology. In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight. View source version on CONTACT: Media Contact Mai Duong (Ms.) FPT Corporation FPT Software PR Manager [email protected] KEYWORD: VIET NAM SOUTHEAST ASIA ASIA PACIFIC INDUSTRY KEYWORD: TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE HEALTH PHARMACEUTICAL DATA MANAGEMENT ARTIFICIAL INTELLIGENCE SOURCE: FPT Corporation Copyright Business Wire 2025. PUB: 06/06/2025 07:13 AM/DISC: 06/06/2025 07:12 AM


Associated Press
34 minutes ago
- Associated Press
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]


Medscape
36 minutes ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.